Ahmed Zayed Obeidat, MD, PhD

Ahmed Zayed Obeidat MD, PhD; Ravi Dukkipati, MD; and Gabriel Pardo, MD, FAAN, share key takeaways for clinicians treating RRMS.

Expert neurologists highlight upcoming agents for the treatment of RRMS, focusing on biomarkers.

Experts in neurology provide insight on challenges that arise with the use of generic DMTs in RRMS treatment, such as cost to the patient.

Ahmed Zayed Obeidat MD, PhD; Ravi Dukkipati, MD; and Gabriel Pardo, MD, FAAN, comment on the use of generic DMTs in the treatment of RRMS, highlighting efficacy and safety data as well as level of equivalence to brand name treatments.

Expert neurologists discuss treatment options for a patient with comorbid autoimmune diseases, relapsing/remitting multiple sclerosis, and psoriasis.

Ravi Dukkipati, MD, and Gabriel Pardo, MD, FAAN, review the use of rituximab and other disease-modifying therapies in a patient with an established diagnosis of relapsing/remitting multiple sclerosis.

Ahmed Zayed Obeidat MD, PhD; Ravi Dukkipati, MD; and Gabriel Pardo, MD, FAAN, discuss a patient case with relapsing/remitting multiple sclerosis progression and share considerations for switching treatment.

Expert neurologists review treatment options for a young female with relapsing remitting multiple sclerosis (RRMS).

Ahmed Zayed Obeidat MD, PhD; Ravi Dukkipati, MD; and Gabriel Pardo, MD, FAAN, consider reasons to use generic disease-modifying therapies (DMTs) as a first-line therapy in the treatment of relapsing remitting multiple sclerosis (RRMS).

Experts in neurology highlight factors that lead them to choose certain therapies to treat relapsing remitting multiple sclerosis (RRMS), such as high efficacy in clinical trials.

Gabriel Pardo, MD, FAAN, describes the process that generic RRMS medications have to go through to be approved by the FDA, highlighting the abbreviated new drug application [ANDA] process.

Expert neurologists review availability of generic disease-modifying therapies [DMTs] and the effectiveness of reduced cost to the patient with RRMS

Ravi Dukkipati, MD, and Gabriel Pardo, MD, FAAN, discuss barriers in accessing treatment for patients with RRMS, as well as a lack of appropriate biomarkers to monitor disease progression.

Experts in neurology review recent advances in the treatment landscape of relapse-remitting multiple sclerosis (RRMS) and the ever-present challenge of tailoring treatment to individual patients.

Drs Ahmed Zayed and Mark S. Freedman review emerging therapies in the pipeline and unmet needs in the multiple sclerosis treatment landscape, as well as take-home thoughts.

Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC, provides an overview of the different types of Bruton tyrosine kinase inhibitors (BTKi) in management of MS.

Experts in neurology highlight the factors they consider when switching treatments for a patient with MS.

Ahmed Zayed Obeidat MD, PhD, and Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC, discuss the use of oral cladribine in the treatment of MS.

Experts in neurology present long-term efficacy and safety data of oral DMTs in the treatment of MS and share their perspective on the real-world significance.

Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC, comments on the different modes of administration of DMTs in MS, focusing on oral DMTs.

Experts in neurology assess the risk of disease progression in a patient with MS and identify various biomarkers and diagnostic tools used to detect this.

Drs Ahmed Zayed Obeidat and Mark S. Freedman share considerations for individualized therapy for the management of MS.

Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC, provides an overview of disease-modifying therapies for the treatment of multiple sclerosis.